YH32364 for locally advanced or metastatic EGFR‑overexpressing solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

YH32364 is a bispecific antibody designed to both block EGFR signaling and activate the immune co‑stimulatory receptor 4‑1BB specifically in tumors to boost T cell responses while aiming to reduce liver toxicity seen with earlier 4‑1BB agonists. The study has a Phase 1 dose‑escalation part with up to six dose levels to identify safe doses, followed by a randomized Phase 2 part comparing two selected dose levels to confirm the recommended dose. Treatment is given by IV infusion every two weeks with regular on‑site assessments for safety and tumor measurements. Eligible adults have locally advanced or metastatic solid tumors confirmed to overexpress EGFR and have exhausted standard therapy options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must sign an informed consent form (ICF) prior to any study specific procedures
* ECOG performance status 0 or 1
* Estimated life expectancy of at least 3 months
* A woman must not be breastfeeding
* Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements.

\[Dose Escalation Only\] Locally advanced or metastatic EGFR overexpressing solid tumor\* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy

\* One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors.

* Head and neck squamous cell carcinoma (HNSCC)
* Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC)
* Esophageal squamous cell carcinoma (ESCC)
* Biliary tract cancer (BTC)
* Uterine cervical cancer
* Vulvar cancer
* Urothelial cancer
* Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor)

\[Dose Expansion Only\] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC)\* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy.

Exclusion Criteria:

* Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis
* Have history of a second primary cancer with the exception of

  * curatively treated non-melanomatous skin cancer
  * curatively treated cervical or breast carcinoma in situ, or
  * other malignancy with no known active disease present and no treatment administered during the last 2 years
* Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)
* Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks
* Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis
* Have autoimmune disease that has required systemic treatment
* Infection with human immunodeficiency virus (HIV)
* Active chronic hepatitis B or chronic hepatitis C

\[Prior/Concomitant Therapy\]

* Have received systemic steroid therapy
* Previous treatment with a 4-1BB/CD137-modulating agent
* Have used a live vaccine within 4 weeks
* Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies
* Have received radiation therapy
* Have received cytotoxic chemotherapy

Where it's running

• Korea University Anam Hospital
  Seoul, South Korea Recruiting
• Seoul National University Hospital
  Seoul, South Korea Recruiting
• Severance Hospital
  Seoul, South Korea Recruiting
• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Clinical Operation Team 1
• Email: clinicaltrials@yuhan.co.kr
• Phone: +82-2-828-0150

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and anti-tumor activity of IPN60300 in adults with advanced or metastatic solid tumors

  This trial will test whether injections of IPN60300 are safe and can help control advanced or metastatic solid tumors in adults.

  Recruiting at 10 sites Phase 1/2 Ipsen · New Haven, Connecticut and 11 other locations · NCT07213817

• Evaluating NVL-330 for advanced HER2-altered lung cancer

  This study is testing a new treatment called NVL-330 to see if it can safely help people with advanced lung cancer that has changes in the HER2 gene.

  Recruiting at 20 sites Phase 1 Nuvalent Inc. · Irvine, California and 20 other locations · NCT06521554

• Treatment of advanced solid tumors using ACE2016 cell therapy

  This study is testing a new cell therapy called ACE2016 to see if it can help people with advanced solid tumors that have not improved with other treatments.

  Recruiting at 4 sites Phase 1 Acepodia Biotech, Inc. · San Diego, California and 8 other locations · NCT06415487

• Using topical tretinoin to prevent skin issues from cancer treatment

  This study is testing if a cream called tretinoin can help reduce skin rashes for patients with metastatic colorectal cancer who are receiving certain cancer treatments.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT06358677

• Evaluating NVL-655 for Advanced ALK-Positive Solid Tumors

  This study is testing a new drug called NVL-655 to see if it can safely help people with advanced ALK-positive solid tumors, including non-small cell lung cancer.

  Recruiting at 73 sites Phase 1/2 Nuvalent Inc. · Orange, California and 73 other locations · NCT05384626

• Evaluating NVL-520 for Advanced ROS1-positive Solid Tumors

  This study is testing a new drug called NVL-520 to see if it can safely help people with advanced solid tumors that have a specific genetic change called ROS1.

  Recruiting at 58 sites Phase 1/2 Nuvalent Inc. · Orange, California and 62 other locations · NCT05118789

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.